News | Stents Drug Eluting | November 02, 2016

Independent Study Finds Biodegradable Polymer Stents Provide No Clinical Benefit Over Resolute Integrity DES

BIO-RESORT demonstrates excellent clinical outcomes for Medtronic Resolute Integrity drug-eluting stent

Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016

November 2, 2016 — Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer drug-eluting stents (BP-DES), using the Boston Scientific Synergy and Biotronik Orsiro, to a durable polymer Resolute Integrity drug-eluting stent (DP-DES) from Medtronic. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity.

The results were presented during a Late-Breaking Clinical Trial session at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Oct. 29-Nov. 3 in Washington, D.C., and simultaneously published in The Lancet.

“In patients with coronary artery disease treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer may delay arterial healing and even cause adverse clinical events,”  M.D., Ph.D., co-director of the Department of Cardiology at Thoraxcentrum Twente, professor of cardiology at University of Twente in the Netherlands, principal investigator of the trial and presenter of the data at TCT. “Biodegradable polymer stents might improve long-term outcomes, but studies with early biodegradable polymer stents that had thick stainless steel struts (120 µm) showed equivocal results. However, very thin-strut (60–81µm) biodegradable polymer stents that have flexible designs and thin, refined coatings are now available.” 

As the authors write in The Lancet manuscript, "Neither of these [biodegradable] stents have [previously] been compared with the new-generation thin-strut durable polymer zotarolimus-eluting stent (Resolute Integrity) — an established device with excellent clinical outcomes."

In the BIO-RESORT study, the primary composite endpoint of target vessel failure at one-year showed no statistically significant difference in outcomes for the Resolute Integrity DP-DES treated group (N=1173) at 5.4 percent compared to 4.7 percent with the Synergy BP-DES (N=1172) arm and 4.7 percent with the Orsiro (N=1169) BP-DES am (difference of 0.7 percent; p=0.45 for Boston Scientific Synergy and p=0.46 for Biotronik Orsiro). The one-year outcomes also found no statistically significant difference in stent thrombosis between Resolute Integrity and the BP-DES groups (difference of 0.1 percent; p=0.77).

"The BIO-RESORT trial demonstrates the continued value of high-quality randomized DES trials in true all-comers, reflecting real-world clinical practice. BIO-RESORT included the greatest proportion of patients with STEMI [ST elevated myocardial infarction] — more than 30 percent — of all previous randomized stent trial in all-comers and one of the greatest proportions of patients with acute coronary syndromes at almost 70 percent," von Birgelen said. "As in our previous randomized study, the DUTCH PEERS trial, patients treated with the Resolute Integrity stent showed low and favorable one-year clinical event rates. The stent was an excellent challenge for the two novel very-thin strut biodegradable polymer drug-eluting stents to compare with, and the results showed no significant difference in the 12-month incidence of the composite primary endpoint. The long-term results of the BIO-RESORT trial will be of great interest, too."

The Resolute Integrity DES features Continuous Sinusoid Technology, which provides excellent deliverability and conformability to the vessel wall, according to Medtronic. The durable polymer used with the Resolute Integrity DES, called BioLinx, was specifically designed for DES use. BioLinx is non-inflammatory and non-thrombogenic, which allows for rapid and complete endothelial healing, while minimizing the risk of stent thrombosis. Long-term performance of BioLinx in over 16,000 patients studied in the RESOLUTE clinical program, demonstrated low stent thrombosis in real-world patients through five years, as well as a low risk for stent thrombosis with interruption or discontinuation of dual antiplatelet therapy (DAPT) after one month. The Resolute Integrity stent offers a treatment option with a proven long-term safety and efficacy profile that is yet to be established for new DES designs with biodegradable polymers, according to the company.

 

Three TCT 2016 Trials Failed To Show Differences in Patient Outcomes With Bioreorbable Polymers 

There were three trials presented at TCT 2016 that compared metallic stents with bioresorbable polymers (including the Biosensor's Osiro and the Boston Scientific Synergy) to durable polymer stents (including the Medtronic Endeavor and Abbott Xience V). The data from thee trials all showed there was no statistical difference between bioresorbable and non-bioresorbable polymer metallic stents. There were high hopes that bioresorbable polymer metallic DES would be a big step forward to further reduce rates of late stent thrombosis and in-stent restenosis.

Read the related articles:

Bioresorbable Polymer Metallic Stents Did Not Improve Outcomes Compared to Durable Polymer Stents

Imaging Study Finds Good Stent Strut Coverage, Low Restenosis With Bioresorbable and Durable Polymer DES

 

The BIO-RESORT study was supported by Boston Scientific, Biotronik and Medtronic.

For more information: www.medtronic.com

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart| December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Overlay Init